Diabetologia

, Volume 34, Issue 2, pp 129–132

Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in Type 2 (non-insulin-dependent) diabetic patients

  • T. Sanke
  • T. Hanabusa
  • Y. Nakano
  • C. Oki
  • K. Okai
  • S. Nishimura
  • M. Kondo
  • K. Nanjo
Rapid Communications

Summary

Fasting plasma islet amyloid polypeptide concentrations and their responses to an oral glucose load were determined in non-diabetic control subjects and patients with abnormal glucose tolerance in relation to the responses of insulin or C-peptide. Plasma islet amyloid polypeptide was measured by radioimmunoassay. In the non-diabetic control subjects, fasting plasma islet amyloid polypeptide was 6.4±0.5 fmol/ml (mean ± SEM) and was about 1/7 less in molar basis than in insulin. The fasting islet amyloid polypeptide level rose in obese patients and fell in patients with Type 1 (insulin-dependent) diabetes mellitus. In non-obese patients with impaired glucose tolerance and Type 2 (non-insulin-dependent) diabetic patients without insulin therapy, the level was equal to that of the control subjects, but a low concentration of islet amyloid polypeptide relative to insulin or C-peptide was observed in the non-obese Type 2 diabetic group. The patterns of plasma islet amyloid polypeptide responses after oral glucose were similar to those of insulin or C-peptide. However, compared to non-obese patients, a hyper-response of islet amyloid polypeptide relative to C-peptide was noted in obese patients who had a hyper-response of insulin relative to C-peptide. This study suggests that basal hypo-secretion of islet amyloid polypeptide relative to insulin exists in non-obese Type 2 diabetes and that circulating islet amyloid polypeptide may act physiologically with insulin to modulate the glucose metabolism.

Key words

Islet amyloid polypeptide amylin diabetes mellitus fasting concentration oral glucose tolerance test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84: 3881–3885CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628–8632CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ, Porte D, Jr (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39: 634–638CrossRefPubMedGoogle Scholar
  4. 4.
    Sowa R, Sanke T, Hirayama J, Tabata H, Furuta H, Nishimura S, Nanjo K (1990) Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 33: 118–120CrossRefPubMedGoogle Scholar
  5. 5.
    Molina JM, Cooper GJS, Leighton B, Olefsky JM (1990) Induction of insulin resistance in vivo by amylin and calcitonin generelated peptide. Diabetes 39: 260–265CrossRefPubMedGoogle Scholar
  6. 6.
    Butler PC, Chou J, Carter WB, Wang Y-N, Bu B-H, Chang D, Chang J-K, Rizza RA (1990) Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39: 752–756CrossRefPubMedGoogle Scholar
  7. 7.
    Mitsukawa T, Takemura J, Asai J, Nakazato M, Kamgawa K, Matsuo H, Matsukura S (1990) Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 39: 639–642CrossRefPubMedGoogle Scholar
  8. 8.
    Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Bloom SR (1990) Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 33: 115–117CrossRefPubMedGoogle Scholar
  9. 9.
    Asano T, Kanatsuka A, Sakurada M, Makino E, Yamamoto T, Okumura M, Yoshida S, Kajinuma H (1990) Kinetic studies of biosynthetic human C-peptide in normal subjects and non-insulin dependent diabetic patients. J Japan Diab Soc 33: 359–363Google Scholar
  10. 10.
    Westermark P, Wilander E, Westermark GT, Johnson KH (1987) Islet amyloid polypeptide-like immunoreactivity in the islet B cells of Type 2 (non-insulin-dependent) diabetic and nondiabetic individuals. Diabetologia 30: 887–892PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • T. Sanke
    • 1
  • T. Hanabusa
    • 1
  • Y. Nakano
    • 1
  • C. Oki
    • 1
  • K. Okai
    • 1
  • S. Nishimura
    • 1
  • M. Kondo
    • 1
  • K. Nanjo
    • 1
  1. 1.The First Department of MedicineWakayama University of Medical ScienceWakayamaJapan

Personalised recommendations